Keeley Teton Advisors LLC Takes $335,000 Position in DENTSPLY SIRONA Inc. $XRAY

Key Points

• Keeley Teton Advisors LLC made a new investment of $335,000 in DENTSPLY SIRONA Inc., acquiring 22,453 shares during the first quarter.
• Several institutional investors have also increased their holdings in DENTSPLY SIRONA, leading to a collective ownership of 95.70% of the company's stock.
• DENTSPLY SIRONA announced a quarterly dividend of $0.16 per share, reflecting an annual yield of 4.5% for shareholders of record by September 26.

Keeley Teton Advisors LLC purchased a new position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 22,453 shares of the medical instruments supplier's stock, valued at approximately $335,000.

A number of other large investors also recently bought and sold shares of XRAY. Vanguard Group Inc. grew its position in DENTSPLY SIRONA by 2.8% in the 1st quarter. Vanguard Group Inc. now owns 20,740,589 shares of the medical instruments supplier's stock valued at $309,864,000 after acquiring an additional 557,329 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of DENTSPLY SIRONA by 11.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 13,961,759 shares of the medical instruments supplier's stock worth $208,590,000 after purchasing an additional 1,412,517 shares during the last quarter. Fuller & Thaler Asset Management Inc. increased its stake in DENTSPLY SIRONA by 4.7% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 12,077,949 shares of the medical instruments supplier's stock worth $180,445,000 after buying an additional 538,531 shares during the period. Lazard Asset Management LLC lifted its holdings in DENTSPLY SIRONA by 23.0% during the 4th quarter. Lazard Asset Management LLC now owns 8,044,228 shares of the medical instruments supplier's stock valued at $152,678,000 after buying an additional 1,505,928 shares in the last quarter. Finally, AQR Capital Management LLC lifted its holdings in DENTSPLY SIRONA by 245.1% during the 4th quarter. AQR Capital Management LLC now owns 2,893,023 shares of the medical instruments supplier's stock valued at $54,389,000 after buying an additional 2,054,767 shares in the last quarter. Hedge funds and other institutional investors own 95.70% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on XRAY shares. Barrington Research dropped their target price on shares of DENTSPLY SIRONA from $21.00 to $18.00 and set an "outperform" rating on the stock in a research note on Friday, August 8th. UBS Group dropped their price objective on DENTSPLY SIRONA from $25.00 to $24.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Stifel Nicolaus reduced their price objective on DENTSPLY SIRONA from $19.00 to $17.00 and set a "hold" rating on the stock in a report on Friday, August 8th. Wall Street Zen cut DENTSPLY SIRONA from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Finally, Wells Fargo & Company dropped their price target on DENTSPLY SIRONA from $16.00 to $15.00 and set an "equal weight" rating on the stock in a research report on Friday, August 8th. Two research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $18.64.

DENTSPLY SIRONA Stock Down 0.1%

DENTSPLY SIRONA stock opened at $14.33 on Thursday. The company has a quick ratio of 1.11, a current ratio of 1.69 and a debt-to-equity ratio of 1.13. The firm has a market cap of $2.86 billion, a P/E ratio of -3.02, a P/E/G ratio of 0.89 and a beta of 0.94. The business has a fifty day moving average of $15.19 and a two-hundred day moving average of $15.42. DENTSPLY SIRONA Inc. has a twelve month low of $12.16 and a twelve month high of $27.48.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $0.52 EPS for the quarter, topping the consensus estimate of $0.50 by $0.02. The firm had revenue of $936.00 million during the quarter, compared to analyst estimates of $929.67 million. DENTSPLY SIRONA had a positive return on equity of 16.33% and a negative net margin of 25.85%.The business's revenue for the quarter was down 4.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.49 EPS. DENTSPLY SIRONA has set its FY 2025 guidance at 1.800-2.000 EPS. On average, analysts forecast that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current fiscal year.

DENTSPLY SIRONA Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 10th. Shareholders of record on Friday, September 26th will be issued a $0.16 dividend. The ex-dividend date is Friday, September 26th. This represents a $0.64 dividend on an annualized basis and a yield of 4.5%. DENTSPLY SIRONA's payout ratio is currently -13.50%.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.